BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 15898000)

  • 1. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis.
    Tewary P; Jain M; Sahani MH; Saxena S; Madhubala R
    J Infect Dis; 2005 Jun; 191(12):2130-7. PubMed ID: 15898000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
    Tewary P; Saxena S; Madhubala R
    Vaccine; 2006 Mar; 24(13):2409-16. PubMed ID: 16413950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
    Sharma A; Madhubala R
    J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.
    Rafati S; Zahedifard F; Nazgouee F
    Vaccine; 2006 Mar; 24(12):2169-75. PubMed ID: 16325969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.
    Sukumaran B; Tewary P; Saxena S; Madhubala R
    Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.
    Rafati S; Zahedifard F; Azari MK; Taslimi Y; Taheri T
    Exp Parasitol; 2008 Mar; 118(3):393-401. PubMed ID: 18093586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
    Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS; Bayih AG; Gedamu L
    Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
    Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
    Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
    Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
    Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of protective immune responses induced by Toxoplasma gondii dense granule antigen 7 (GRA7) against toxoplasmosis in mice using a prime-boost vaccination strategy.
    Min J; Qu D; Li C; Song X; Zhao Q; Li XA; Yang Y; Liu Q; He S; Zhou H
    Vaccine; 2012 Aug; 30(38):5631-6. PubMed ID: 22789504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK; Naskar K; De T
    Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection.
    Carter KC; Henriquez FL; Campbell SA; Roberts CW; Nok A; Mullen AB; McFarlane E
    Vaccine; 2007 May; 25(22):4502-9. PubMed ID: 17418459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmaniasis: current status of vaccine development.
    Sukumaran B; Madhubala R
    Curr Mol Med; 2004 Sep; 4(6):667-79. PubMed ID: 15357215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced immunogenicity of an anti-caries vaccine encoding a cell-surface protein antigen of Streptococcus mutans by intranasal DNA prime-protein boost immunization.
    Li Y; Jin J; Yang Y; Bian Z; Chen Z; Fan M
    J Gene Med; 2009 Nov; 11(11):1039-47. PubMed ID: 19718694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.